CCL19 and B-cell chronic lymphocytic leukemia: These two characteristics (modulation of migration and increased cell survival by CCL19) are essential for the creation and maintenance of proliferative centres in B-CLL and are supportive of the concept of CCR7 antagonism as a therapeutic target in B-CLL [34].